News
News
Upcoming Events
Subscribe
Our Company
Our Story
Our Vision
Board of Directors
Alzinova Team
Advisers & Collaborators
Patients & Families
Alzheimer's Patients
Impact on Society
The Unmet Medical Need
R & D
Alzheimer's Disease
Our Programs
Specific Targeting of Toxic Aβ Oligomers
The AβCC Peptide™ Technology
Scientific Presentations
Investors
Overview
Rights Issue / Företrädesemission 2025
Press Releases
English
Swedish
Subscribe
Presentations
Board and Management
The Share
Financial Reports
Financial Reports - English
Financial Reports – Swedish
Financial Calendar
Corporate Governance
General Meetings
IR Contact
Rights Issue 2025
Career
Contact
News
News
Upcoming Events
Subscribe
Our Company
Our Story
Our Vision
Board of Directors
Alzinova Team
Advisers & Collaborators
Patients & Families
Alzheimer's Patients
Impact on Society
The Unmet Medical Need
R & D
Alzheimer's Disease
Our Programs
Specific Targeting of Toxic Aβ Oligomers
The AβCC Peptide™ Technology
Scientific Presentations
Investors
Overview
Rights Issue / Företrädesemission 2025
Press Releases
English
Swedish
Subscribe
Presentations
Board and Management
The Share
Financial Reports
Financial Reports - English
Financial Reports – Swedish
Financial Calendar
Corporate Governance
General Meetings
IR Contact
Rights Issue 2025
Career
Contact
Home
/
Investors
/
Rights Issue 2022
Rights issue / Företrädesemission 2022
Rights Issue 2022
